Newbridge Financial Services Group Inc. Buys New Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Newbridge Financial Services Group Inc. bought a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the fourth quarter, Holdings Channel reports. The institutional investor bought 300 shares of the biotechnology company’s stock, valued at approximately $36,000.

Other large investors have also modified their holdings of the company. Simplify Asset Management Inc. raised its stake in shares of Sarepta Therapeutics by 84.6% in the third quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock valued at $24,105,000 after purchasing an additional 88,474 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after purchasing an additional 44,306 shares in the last quarter. Summit Partners Public Asset Management LLC raised its stake in shares of Sarepta Therapeutics by 547.9% in the third quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock valued at $17,250,000 after purchasing an additional 116,800 shares in the last quarter. Larson Financial Group LLC raised its stake in shares of Sarepta Therapeutics by 1,649.8% in the third quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock valued at $1,093,000 after purchasing an additional 8,249 shares in the last quarter. Finally, abrdn plc raised its stake in shares of Sarepta Therapeutics by 30.7% in the third quarter. abrdn plc now owns 431,098 shares of the biotechnology company’s stock valued at $53,935,000 after purchasing an additional 101,253 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now owns 22,840 shares of the company’s stock, valued at $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now directly owns 5,880 shares in the company, valued at $738,234. This trade represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

Sarepta Therapeutics Price Performance

Shares of SRPT stock opened at $109.68 on Wednesday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics, Inc. has a 52 week low of $102.15 and a 52 week high of $173.25. The stock has a market capitalization of $10.48 billion, a PE ratio of 87.74 and a beta of 0.75. The stock’s fifty day moving average is $120.49 and its 200-day moving average is $125.33.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Royal Bank of Canada restated an “outperform” rating and issued a $182.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 21st. Deutsche Bank Aktiengesellschaft assumed coverage on Sarepta Therapeutics in a research report on Tuesday. They issued a “hold” rating and a $136.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a research report on Monday, January 27th. Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and upped their price target for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. Finally, Piper Sandler lowered their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $176.77.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.